June 28, 2026
Breaking Bad, but make it biotech
Guy in his basement creates a drug to treat Alzheimer's disease using AI
Basement miracle or biotech ego trip? The internet cannot agree
TLDR: A scientist says he made a possible Alzheimer’s drug in a garage lab with AI help, and that huge claim grabbed attention fast. But the comments were the real spectacle: some praised the skill, while others mocked the hype and warned that inventing a chemical is not the same as proving it works.
A man says he invented a new Alzheimer’s drug in a garage lab, with a tiny vial and a giant claim to match — and the internet instantly turned it into a courtroom, a comedy club, and a fact-checking squad all at once. The post says the drug, PAC-832, was designed and made at home with help from artificial intelligence, and that alone was enough to set off alarms, awe, and a whole lot of side-eye.
The biggest fight in the comments was over what actually happened here. Some readers rolled their eyes at the headline-sized version of events, saying this wasn’t some random basement wizard suddenly curing memory loss with a chatbot. One commenter bluntly pointed out that the guy appears to have serious credentials, including a Harvard PhD, and may have used AI more as a helper than as a magical drug-inventing brain. In other words: genius home lab story or very online exaggeration?
Then came the darker, funnier panic. One person basically asked why the AI didn’t hit the brakes with a “sorry, can’t help with that” warning, while another demanded experts rank this on the scale from “promising treatment” to “AI psychosis.” Ouch. And perhaps the sharpest reality check of all: people kept repeating that saying you created a drug to treat Alzheimer’s is not the same as proving it actually treats Alzheimer’s. The crowd may love the garage-lab fantasy, but in the comments, skepticism stole the show.
Key Points
- •The article claims a new drug called PAC-832 was invented to treat Alzheimer’s disease.
- •PAC-832 is described in the post as the world’s first selective GalR1 antagonist.
- •The author says the compound was personally designed and synthesized.
- •The work is said to have been carried out in a chemistry lab built in a garage.
- •The article content provides no clinical evidence, trial results, or third-party validation.